Intensity Therapeutics opened lower at $3.25, compared with its previous close of $3.28. In the last trading session, the stock traded between $3.10 and $3.34. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Intensity Therapeutics is now worth
$ 2.07
Resulting in a loss of
$ 97.93 (97.93%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.20 (-6.10%)
Day High
$3.34
Day Low
$3.10
Day Open
$3.25
Prev Close
$3.28
Volume
10,958
1W Return
-13.70%
1M Return
-9.28%
3M Return
-26.75%
6M Return
-38.40%
1Y Return
-68.41%
Fundamentals
Market Cap ($ Mn)
10
PE Ratio
-
PB Ratio
1.35
PEG Ratio
-
ROE
-236.53%
ROCE
-235.65%
EPS (TTM)
$-1.08
Investment Returns
1 Week
-13.70%
1 Month
-9.28%
3 Months
-26.75%
6 Months
-38.40%
9 Months
-67.07%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
5Nov
Intensity Therapeutics Q3FY26 Results: Net loss widens to $3.5 million
Net loss widened 33% YoY to $3.5 million in Q3 2026, missing consensus estimates. R&D expenses rose to $2.4 million driven by resumed clinical trials and manufacturing. Cash position stands at $8.5 million with guided monthly burn increasing to $1 million in Q4. Enrollment resumed in Phase 3 sarcoma and Phase 2 TNBC studies with updated assessment criteria.
7 days ago
11Aug
Intensity Therapeutics Q2 Results: EPS loss narrows 67% YoY
Intensity Therapeutics posted Q2 EPS of $(1.11), matching analyst estimates and showing a 66.96% reduction in losses compared to $(3.36) per share in the prior year period. This significant narrowing of losses highlights improved financial efficiency despite ongoing net deficits.
3mo ago
15Jul
Intensity Therapeutics resumes INVINCIBLE-4 trial dosing in Switzerland
Intensity Therapeutics, Inc. has resumed patient dosing in its INVINCIBLE-4 Phase 2 clinical trial for triple-negative breast cancer (TNBC) in Switzerland following a protocol amendment submitted in March 2026. The trial evaluates INT230-6 administered before standard-of-care neoadjuvant immuno-chemotherapy, with the primary endpoint being pathological complete response (pCR). The study aims to enroll an additional 47 patients across Switzerland and France.
